Evidence map›Paper›PMID 42429050›Full record

ReviewInternational journal of molecular medicine2026

Protective effects of Astragaloside IV on various liver diseases: From chemistry to herbal medicines (Review).

Jialu Shi, Xiaoyu Zhou, Jiabin Wu, Liru Zeng, Xia Wang, Wei Li, Xiao Huang, Xiaoyu Deng, Wenhong Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jialu Shi *School of Physical Education and Health, Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.
Xiaoyu Zhou *Key Laboratory of Bone Biomaterials and Dong Medicine-Regulated Organoid Regeneration of Hunan Provincial Universities, Biomedical Research Institute, Hunan University of Medicine, Huaihua, Hunan 418000, P.R. China.
Jiabin WuShanghai Key Laboratory of Human Performance (Shanghai University of Sport), Shanghai University of Sport, Shanghai 200438, P.R. China.
Liru ZengKey Laboratory of Bone Biomaterials and Dong Medicine-Regulated Organoid Regeneration of Hunan Provincial Universities, Biomedical Research Institute, Hunan University of Medicine, Huaihua, Hunan 418000, P.R. China.
Xia WangKey Laboratory of Bone Biomaterials and Dong Medicine-Regulated Organoid Regeneration of Hunan Provincial Universities, Biomedical Research Institute, Hunan University of Medicine, Huaihua, Hunan 418000, P.R. China.
Wei LiKey Laboratory of Bone Biomaterials and Dong Medicine-Regulated Organoid Regeneration of Hunan Provincial Universities, Biomedical Research Institute, Hunan University of Medicine, Huaihua, Hunan 418000, P.R. China.
Xiao HuangKey Laboratory of Bone Biomaterials and Dong Medicine-Regulated Organoid Regeneration of Hunan Provincial Universities, Biomedical Research Institute, Hunan University of Medicine, Huaihua, Hunan 418000, P.R. China.
Xiaoyu DengKey Laboratory of Bone Biomaterials and Dong Medicine-Regulated Organoid Regeneration of Hunan Provincial Universities, Biomedical Research Institute, Hunan University of Medicine, Huaihua, Hunan 418000, P.R. China.
Wenhong WangSchool of Physical Education and Health, Zunyi Medical University, Zunyi, Guizhou 563000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numerous liver diseases are characterized by late diagnosis, rapid progression and high incidence, seriously threatening public health. Though widely used, traditional treatments such as drug therapy, resection and transplantation have substantial limitations. Therefore, developing novel preventive strategies and specialized therapies is crucial. As Chinese medicine continues to modernize, increasing evidence suggests that certain Chinese medicine ingredients can protect the liver. Astragaloside IV (AS‑IV) is a natural saponin extracted from the root of the traditional herb

Indexed as

Drugs, Chinese HerbalLiver DiseasesProtective AgentsSaponinsTriterpenesAnimalsHumansSignal Transductionastragaloside ADrugs, Chinese HerbalProtective AgentsSaponinsTriterpenesAS‑IVhepatoprotective effectliver diseasemolecular mechanisms

Identifiers

PMID42429050
PMCPMC13378600

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.